Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest Down 69.8% in June

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 26,939 shares, a drop of 69.8% from the June 15th total of 89,259 shares. Currently, 1.7% of the company’s shares are sold short. Based on an average trading volume of 337,966 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Scinai Immunotherapeutics has an average rating of “Sell”.

Institutional Investors Weigh In On Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC grew its stake in Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 28,630 shares of the company’s stock after buying an additional 17,031 shares during the quarter. Citadel Advisors LLC owned 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 58.41% of the company’s stock.

Scinai Immunotherapeutics Trading Down 1.9%

Shares of SCNI traded down $0.00 during midday trading on Monday, hitting $0.25. 76,667 shares of the stock were exchanged, compared to its average volume of 1,709,528. Scinai Immunotherapeutics has a 52-week low of $0.24 and a 52-week high of $3.48. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.35 and a current ratio of 1.35. The stock has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.63. The firm has a market cap of $974,160.00, a P/E ratio of -0.23 and a beta of 2.11.

Scinai Immunotherapeutics (NASDAQ:SCNI) last released its earnings results on Wednesday, April 1st. The company reported $3.80 earnings per share for the quarter. The firm had revenue of $0.27 million during the quarter.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.